The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of<a href="https://solaci.org/en/2015/06/24/congress-item-6888/" title="Read more" >...</a>
ISAR-DESIRE 3 did not show that paclitaxel-eluting balloon may be useful for treating restenosis of a sirolimus–eluting stent. This study tests the safety and efficacy of a paclitaxel-eluting balloon versus a paclitaxel-eluting stent in cases of in-stent drug-eluting restenosis. We included 220 patients with in-stent restenosis of a drug-eluting stent ball randomized at a 1:1<a href="https://solaci.org/en/2015/06/24/congress-item-6601/" title="Read more" >...</a>
This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable polymer everolimus eluting stent. The study seeks to prove superiority versus the first generation paclitaxel-eluting stent and non-inferiority versus surgery using historical data. We<a href="https://solaci.org/en/2015/06/24/congress-item-6412/" title="Read more" >...</a>
This prospective multicenter study randomized 476 patients 2:1 to paclitaxel eluting balloon versus conventional balloon for femoropopliteal region lesions with the primary objective of assessing death, free amputationsurvival and reintervention at 6 months. At 6 months follow-up a higher rate of restenosis with conventional balloon was observed.These are preliminary results and we must wait for<a href="https://solaci.org/en/2015/06/24/congress-item-6293/" title="Read more" >...</a>
The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a<a href="https://solaci.org/en/2015/06/24/congress-item-6300/" title="Read more" >...</a>
Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or<a href="https://solaci.org/en/2015/04/27/n-5160/" title="Read more" >...</a>
Original title: Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. Reference: Laura Mauri et al. N Engl J Med 2014;371:2155-66. Dual antiplatelet therapy is recommended after a drug-eluting stent to prevent thrombotic complications. The clinical benefit of this scheme it is not clear beyond one year. Patients were registered to receive a<a href="https://solaci.org/en/2015/01/13/n-4901/" title="Read more" >...</a>
Original title: Drug-Eluting Balloons for the Treatment of the Superficial Femoral Artery In-Stent Restenosis. 2-Year Follow-Up. Reference: Vittorio Virga et al. J Am Coll Cardiol Intv 2014;7:411–5. Although the use of the self-expanding nitinol stent has improved angioplasty outcomes in femoropopliteal territory, restenosis remains a challenge still affecting at least 25% of the population in the first year.<a href="https://solaci.org/en/2014/07/08/n-4586/" title="Read more" >...</a>
Original title: Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Reference: Eur Heart J. 2014 May 21. pii: ehu213. (Epub ahead of print). The SYNTAX study was one of the largest randomized clinical studies comparing long-term results of angioplasty versus surgery in multivessel disease and /or<a href="https://solaci.org/en/2014/07/04/n-4579/" title="Read more" >...</a>
Original title: Meta-analysis of randomized clinical trials comparing short term -vs- long term dual antiplatelet therapy following drug eluting stents. Reference: El-Hayek G et al. Am J Cardiol. 2014; Epub ahead of print. This meta-analysis examined the data of four randomized and controlled studies (EXCELLENT, PRODIGY, RESET y OPTIMIZE) including 8157 patients receiving sirolimus, paclitaxel, everolimus or zotarolimus<a href="https://solaci.org/en/2014/06/24/n-4551/" title="Read more" >...</a>